| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1096-100MG | Bromocriptine mesylate | 100mg | $137.00 | |
| GBM-1096-500MG | Bromocriptine mesylate | 500mg | $546.00 |
| Bioassays Specification | |
| Bio-Activity | Dopamine D2/D3 agonist |
| Chemical Name | (+)-2-Bromo-12’-hydroxy-2’-(1-methylethyl)-5’-(2-methylpropyl)-ergotaman-3’,6,’18-trione methanesulfonate |
| Function / Pharmacology | Dopamine D2 receptor agonist. Inhibits prolactin production3. Decreases cocaine self-administration in the rat4. Active in vivo. |
| CAS# | 22260-51-1 |
| MW | 750.7 |
| Molecular Formula | C32H40BrN5O5 • CH3SO3H |
| Solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 6 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Nilsson and Hokfelt (1978), Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise, and during insulin induced hypoglycemia; Acta Endocrinol., Supp. 216 83 2) Seeman and Van Tol (1994), Dopamine receptor pharmacology; Trends Pharmacol. Sci., 15 264 3) Carvalho et al. (2015), Maternal prolactin inhibition causes changes in leptin at 22- and 30-day old pups; Horm. Metab. Res., 47 528 4) Hubner and Koob (1990), Bromocriptine produces decreases in cocaine self-administration in the rat; Neuropsychopharmacol., 3 101 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Dopamine D2/D3 agonist |
| Chemical Name | (+)-2-Bromo-12’-hydroxy-2’-(1-methylethyl)-5’-(2-methylpropyl)-ergotaman-3’,6,’18-trione methanesulfonate |
| Function / Pharmacology | Dopamine D2 receptor agonist. Inhibits prolactin production3. Decreases cocaine self-administration in the rat4. Active in vivo. |
| CAS# | 22260-51-1 |
| MW | 750.7 |
| Molecular Formula | C32H40BrN5O5 • CH3SO3H |
| Solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 6 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Nilsson and Hokfelt (1978), Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise, and during insulin induced hypoglycemia; Acta Endocrinol., Supp. 216 83 2) Seeman and Van Tol (1994), Dopamine receptor pharmacology; Trends Pharmacol. Sci., 15 264 3) Carvalho et al. (2015), Maternal prolactin inhibition causes changes in leptin at 22- and 30-day old pups; Horm. Metab. Res., 47 528 4) Hubner and Koob (1990), Bromocriptine produces decreases in cocaine self-administration in the rat; Neuropsychopharmacol., 3 101 |
| Protein Specification | |
| Purity | >98% |
